جهت دسترسی به کاربرگه ی زیر، از این لینک استفاده کنید. http://dl.kums.ac.ir/handle/Hannan/361414
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFukuhara, Shinichien_US
dc.contributor.authorShiomi, Suzunaen_US
dc.contributor.authorYang, Boen_US
dc.contributor.authorKim, Karenen_US
dc.contributor.authorBolling, Steven F.en_US
dc.contributor.authorHaft, Jonathanen_US
dc.contributor.authorTang, Paulen_US
dc.contributor.authorPagani, Francisen_US
dc.contributor.authorPrager, Richard L.en_US
dc.contributor.authorChetcuti, Stanleyen_US
dc.contributor.authorGrossman, P. Michaelen_US
dc.contributor.authorPatel, Himanshu J.en_US
dc.contributor.authorDeeb, G. Michaelen_US
dc.date.accessioned2013en_US
dc.date.accessioned2020-04-25T17:56:29Z-
dc.date.available2020-04-25T17:56:29Z-
dc.date.issued2020en_US
dc.identifier.issnen_US
dc.identifier.other10.1016/j.athoracsur.2019.06.032en_US
dc.identifier.urihttps://doi.org/10.1016/j.athoracsur.2019.06.032en_US
dc.identifier.urihttp://dl.kums.ac.ir/handle/Hannan/361414-
dc.description.abstractBackground: Structural valve degeneration (SVD) is a major flaw of bioprostheses. An apparent increase in the SVD rate has been observed among patients who received the Trifecta bioprosthesis (Abbott Vascular, Santa Clara, CA). Methods: This study retrospectively reviewed 1058 consecutive patients who underwent aortic valve placement with a stented bioprosthesis between January 2011 and December 2015. Patients were grouped into a Trifecta group (508 [48.0%] patients with Trifecta bioprostheses) and a non-Trifecta group (550 [52.0%] patients with other bioprostheses). Results: Patients in the Trifecta group were older (69.7 years vs 64.6 years; P =.001), were more likely female (40.4% vs 28.0%; P =.001), more often had aortic stenosis (85.1% vs 77.1%; P =.001), and received smaller valves (23.0 mm vs 25.0 mm; P <.001) than patients in the non-Trifecta group. SVD occurred in 28 patients (Trifecta, n = 22; non-Trifecta, n = 6) within 7 years. Aortic regurgitation or mixed stenosis/regurgitation was observed as the mode of failure in more than 50% of the Trifecta group, whereas none in non-Trifecta group. The cumulative incidence of SVD was higher in the Trifecta group both in the entire cohort (13.3% vs 4.6%; P =.010) and in the younger cohort (age ≤ 65 years; 27.9% vs 6.9%; P =.004), with a notable increase between 5 and 7 years. Multivariable competing risks regression in the Trifecta group revealed younger age (hazard ratio, 0.56 per 10-point decrease; 95% confidence interval, 0.44 to 0.72; P <.001) to be the sole contributor to SVD. Conclusions: The SVD rate of the Trifecta bioprosthesis has been greater than expected, compared with other bioprostheses, particularly in younger patients. In view of the large number of Trifecta bioprostheses implanted worldwide, further investigation involving other institutions is warranted.en_US
dc.format.extentVOLUME:109en_US
dc.format.extentISSUE:3en_US
dc.format.extentSTARTPAGE:720en_US
dc.format.extentENDPAGES:727en_US
dc.publisherElsevieren_US
dc.relation.haspart2020 AoTS Volume 109 Issue 3 March (14).pdfen_US
dc.subjectMedical Scienceen_US
dc.titleEarly Structural Valve Degeneration of Trifecta Bioprosthesisen_US
dc.typeArticleen_US
dc.journal.volumeVolume 109en_US
dc.journal.issueIssue 3en_US
dc.journal.monthMarchen_US
dc.journal.titleAnnals of Thoracic Surgeryen_US
Appears in Collections:Annals of Thoracic Surgery

Files in This Item:
File Description SizeFormat 
2020 AoTS Volume 109 Issue 3 March (14).pdf1.61 MBAdobe PDFThumbnail
Download    Request a copy


تمامی کاربرگه ها در کتابخانه ی دیجیتال حنان به صورت کامل محافظت می شوند.